Levi & Korsinsky is investigating the Board of Directors of Tobira Therapeutics, Inc. (NASDAQ: TBRA) (“Tobira” or “the Company”) in connection with the sale of the Company to Allergan plc. Under the terms of the transaction, Tobira shareholders will receive $28.35 per share. The deal also includes up to $49.84 per share in Contingent Value Rights, payable upon the successful completion of certain milestones. The deal has a potential approximate value of $1.695 billion.
The investigation concerns whether the Board of Tobira breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Allergan plc is underpaying for Tobira shares.
To receive more information, please fill out the form.